Search results

Page 1 of 5

Your search for atherosclerosis returned 42 results

Order results by:
Download as a CSV:
Target: GPR132 (Class A Orphans)
Consequences of altering gene expression: atherosclerosis in low-density lipoprotein receptor knockout mice. Reduction in aortic lesion coverage, macrophage accumulation
Consequences of altering gene expression: deficiency affects atherosclerosis in a tissue-specific manner. ApoE dependent pro-atherogenic phenotype is observed
Consequences of altering gene expression: ability to engulf apoptotic cells in vitro, and promotes macrophage activation and atherosclerosis in vivo
Consequences of altering gene expression - comment: atherosclerosis. One study investigating GPR132 knockout in LDLR-/- and ApoE-/- mice, suggested an ApoE-dependent
Ligand: darapladib
Comments: clinical drug candidates with potential to reduce the risk of atherosclerosis and associated clinical sequelae .
Clinical use: atherosclerosis, but it failed to meet clinical primary end points and GSK has discontinued further
Immuno Ligand Comments: that may be relevant in conditions other than atherosclerosis that also have an inflammatory component .
Target: regulator of G-protein signaling 1 (R4 family)
Mutations/pathophysiology - disease: Atherosclerosis susceptibility
Mutations/pathophysiology - comment: Vascular diseases: Atherosclerosis AND aortic aneurysms
Target: P2Y1 receptor (P2Y receptors)
Consequences of altering gene expression: P2Y1 receptor deficiency resulted in a reduction of atherosclerosis in ApoE knockout mice.
Physiological function - description: Atherosclerosis enhancement
Ligand: compound 37 [PMID: 29193967]
Immuno Ligand Comments: that may be relevant in conditions other than atherosclerosis that also have an inflammatory component .
Ligand: (S)-23 [PMID: 27933945]
Immuno Ligand Comments: that may be relevant in conditions other than atherosclerosis that also have an inflammatory component .
Ligand: rilapladib
Immuno Ligand Comments: that may be relevant in conditions other than atherosclerosis that also have an inflammatory component .
Ligand: canakinumab
Immuno Ligand Comments: evaluated as an anti-inflammatory therapy for atherosclerosis (for example see Phase 3 clinical trial NCT01327846).
Ligand: BMS-681
Immuno Ligand Comments: chemokine axis for conditions including atherosclerosis, multiple sclerosis, asthma, neuropathic pain, diabetic nephropathy and cancer.
Ligand: AVE 0991
Immuno Ligand Comments: leads to reduced vascular and plaque inflammation in the ApoE-/- mouse model of spontaneous atherosclerosis .

1 2 3 4 5

Target search page
Ligand search page
Pharmacology search page